Brain Wealthy
    What's Hot

    Little Celebrities on Campus Who Will Change College Life | By Reid Zura | Starship Technologies | June 2023

    June 5, 2023

    Inclusiveness in Practice: Starship Technologies Proudly Deployed in LA | By Reid Zura | Starship Technologies | June 2023

    June 1, 2023

    Global Accessibility Awareness Day: Building Accessibility into Technology | By Ed Lovelock | Starship Technologies | May 2023

    May 18, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»Hopes for Antisense Oligonucleotides Remain Strong Despite S… : Neurology Today
    Neurology

    Hopes for Antisense Oligonucleotides Remain Strong Despite S… : Neurology Today

    brainwealthy_vws1exBy brainwealthy_vws1exDecember 15, 2022No Comments12 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Article In Brief

    Two children who were administered an antisense oligonucleotide (ASO) for a severe genetic epilepsy disorder developed hydrocephalus, and one of them died. Experts suggest that while the therapies have potential for these otherwise fatal disorders, they remain highly experimental, and greater efforts should be made to share data from other research and outcomes involving ASOs.

    A 3-year-old girl treated with an antisense oligonucleotide (ASO) for a devastating form of genetically caused epileptic encephalopathy died last year after developing hydrocephalus, the principal investigator of the trial reported in October at the annual meeting of the American Neurological Association.

    Another child treated with the same ASO also developed hydrocephalus but underwent a successful shunt placement, reported Timothy Yu, MD, PhD, a neurologist, associate professor of pediatrics at Harvard Medical School, and an attending physician in the division of genetics and genomics at Boston Children’s Hospital.

    Both children had a severe form of KCNT1 epileptic encephalopathy.

    “Patients with KCNT1 epileptic encephalopathy can have a range of outcomes, but we specifically selected patients with early infantile migrating focal seizures, who have the absolute worst outcomes,” Dr. Yu said.

    “In case series, half of these children die early, with a median age of death of 3 years of age; those that survive continue having dozens of seizures per day and suffer profound neurologic impairment. This severity was critical to our (and our institutional review board’s) decision-making in this project.”

    Dr. Yu previously revealed that the very first child he treated with an ASO, described in a paper published in 2019 in the New England Journal of Medicine, had also died—not because of an adverse event, but because of her disorder’s effects.

    The symptoms in all three girls had initially showed significant improvements. Despite the serious adverse events, Dr. Yu told Neurology Today that he remains committed to the study of ASOs for the treatment of neurologic disorders. Other neurologists and neuroscientists said that they, too, continue to have high hopes for ASOs.

    “I think the promise is high,” Dr. Yu said. “We were shocked to see the seizures respond as well as they did, especially in patient No. 2 [the one who survived]. And yet we know that we also incurred this serious adverse event in both cases. The intervention has the capability of producing transformative change. We just need more studies. I don’t think we will begin to know how successful this approach will be, or not, until we get the numbers up.”

    A measure of how promising scientists continue to view ASOs as a means of targeting neurologic disorders can be seen in the recent establishment of several non profit organizations dedicated to their development.

    The n-Lorem Foundation seeks to develop and provide ASOs free for so-called nano-rare disorders, those affecting fewer than 30 individuals worldwide. Other newly formed groups include the St. Jude’s Center for Experimental Therapeutics, led by J. Paul Taylor, MD, PhD; the Dutch Center for RNA Therapeutics, led by Annemieke Aartsma-Rus, PhD; and the N=1 Collaborative. They seek to not only develop new ASOs but also foster data and share expertise among investigators worldwide.

    Still, these serious adverse events have reinforced the view that use of ASOs for nano-rare disorders, when only a handful of children might receive them, places unique burdens on investigators.

    “The fact that you can develop an ASO is only one part of the equation,” said Dr. Taylor. “The other part is the appropriateness of treating the patient. Do they have a phenotype that can reasonably expect to benefit from the intervention? Do the parents have realistic expectations? Will insurance cover it? How do we do this in a way that is not haphazard? How do we work cooperatively with people doing similar work? I do worry that this field needs to move forward carefully or we’re going to repeat the errors of the gene therapy world.”

    The Development of ASOs

    ASOs, first developed over 20 years ago, are single strands of modified DNA-like molecules engineered to link to a complementary strand of messenger RNA. Rather than replacing a defective sequence, ASOs seek to squelch or restore the action of its target. And unlike in gene therapy, they are designed to link only to the target mRNA, without interfering with any other genetic activity.

    On Sept. 19, 2016, the US Food and Drug Administration (FDA) announced approval of the first ASO for a neurologic disease, eterplirsen (Exondys 51). The injectable drug was developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy for patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, [Essentially, the ASO causes the RNA-editing function in the cell nucleus to skip the portion of the dystrophin gene, exon-51, that contains the mutation. It results in a shorter mRNA, which can be translated into a functional protein.]

    Three months later, the FDA approved a second ASO, nusinersen (Spinraza), developed by Ionis Pharmaceuticals to treat spinal muscular atrophy, estimated to affect one in 10,000 live births.

    “With the treatment, if started early, these kids can lead a normal life,” said Kenneth H. Fischbeck, MD, an NIH distinguished investigator at the National Institute of Neurological Disorders and Stroke. “I still get choked up every time I talk about it. It’s such an amazing thing.”

    figure1

    “We were shocked to see the seizures respond as well as they did, especially in patient No. 2 [the one who survived]. And yet we know that we also incurred this serious adverse event in both cases. The intervention has the capability of producing transformative change. We just need more studies. I don’t think we will begin to know how successful this approach will be, or not, until we get the numbers up.”—DR. TIMOTHY YU

    The following year, Dr. Yu began work on another ASO, which he named milasen after the child for whom he developed it. Six-year-old Mila Makovec was battling a rare form of Batten disease caused by a mutation in the gene MFSD8, which causes neuronal ceroid lipofuscinosis type 7, an invariably progressive and fatal disease. In a paper published in the New England Journal of Medicine in October 2019, Dr. Yu and colleagues described how they had developed milasen within less than a year, finding no serious adverse events and a significant reduction in seizures as determined by serial EEGs and parental seizure diary.

    Although the drug worked as intended, Mila had already developed progressive brain shrinkage prior to beginning the treatment, Dr. Yu told Neurology Today.

    “She did really well the first two years,” he said. “Her seizures came down and stayed low and remained low in the third year. But the progressive brain shrinkage didn’t stop. We and her family saw that she was becoming less responsive and losing her communication skills. At the beginning of her third year, the family decided she had been through enough. She stayed on the drug but moved to palliative care.”

    Mila died on Feb. 11, 2021.

    New Case Details

    At the American Neurological Association (ANA) annual meeting in October, Dr. Yu presented an update on the ASO treatment he had offered to two young girls for KCNT1-associated epilepsy of infancy with migrating focal seizures. Children with this condition have very frequent daily seizures starting in early infancy that remain refractory to anti-seizure medications and have minimal to no milestone development. Often they die as young as age 3.

    “Our group has been pursuing a pilot series of individualized ASO trials, each of them N-of-one or N-of-two,” he said.

    The first girl to be treated, then age 2 ½, was having dozens of seizures per day that were uncontrolled with medication. Even so, she had no underlying metabolic disorder or structural brain abnormality, Dr. Yu reported.

    After developing and testing numerous candidate ASOs, they settled on one that controlled the seizures in a mouse model of the disorder. They were granted an investigational new drug status by the FDA in September 2020 and began intrathecal injections every two weeks, beginning at 10 mg and ramping up to 20 mg at the second dose, 30 mg at the third dose, and 40 mg at the fourth.

    figure2

    “With the treatment, if started early, these kids can lead a normal life. I still get choked up every time I talk about it. It’s such an amazing thing.”—DR. KENNETH H. FISHBECK

    “We settled in at a maintenance dose initially of 40 mg, then went to 60 mg,” Dr. Yu said. “There were reductions in seizure frequency and severity over the first 100 days.”

    The second patient, also age 2 ½, was enrolled a few months later. “The results were quite immediately apparent,” Dr. Yu said during his presentation at the ANA meeting. “At baseline her family had recorded five to 15 seizures daily. After the 20 mg dose, there was a slight downward trend. The trend continued at 30 mg. At 40, they really fell: zero to four per day. They stayed in this range for the next 50 days. It was a pretty striking response.”

    Then, he said: “Now for the sad news. Both participants developed serious and arguably life-threatening events. In the eleventh month of the trial, on a routine study MRI, patient number one was found to have developed advanced hydrocephalus. Frankly it came as a shock. The patient had been doing well in the months leading up to the scan. We don’t know exactly when it developed.”

    The trial was paused, and after investigation and consideration of options, he reported, “the family withdrew from the trial, and there was a transition to comfort care.”

    The second patient was also hospitalized after her fourth dose, initially for evaluation of dystonia. “She was found to have enlarging brain ventricles on serial scans, indicative of early stage hydrocephalus.” Dr. Yu said. “She underwent placement of a shunt, which resolved the hydrocephalus and led to successful discharge from the hospital.”

    He noted that hydrocephalus had not been seen in any of the preclinical animal studies, nor in preclinical animal studies of other FDA-approved or investigational ASOs. “We inquired with other researchers,” Dr. Yu said at the meeting. “No one else had seen this.”

    His group did notice, however, that a cohort of patients in a clinical trial of an ASO developed for Huntington’s disease by Ionis were reported in 2020 to have developed dose-dependent ventricular enlargement.

    “Our hypothesis is that we may have uncovered a new risk of ASO,” Dr. Yu said at the meeting. Perhaps, he said, the reaction occurred due to an overly aggressive treatment schedule.

    “Case No. 2 has been monitored for a year,” he said. “We’re considering a dose reduction and resuming treatment.”

    The Question of Data Sharing

    In late October, just days after Dr. Yu had given his report at the ANA meeting, approximately 50 experts in ASOs and the development of treatments for rare diseases attended a meeting on the subject at St. Jude. Dr. Fischbeck moderated a session on the importance of data sharing, particularly in trials involving only one or a handful of patients.

    figure3

    “There’s an awful lot of scientific research that never gets published but that could be very helpful. There is great potential with these ASOs, but we need to remember that these are experimental treatments. We’re learning that the human response is different from what was expected based on animal studies. It’s very important that we’re very cautious and that there is good reporting of results, both good and bad, as widely as possible.”—DR. JONATHAN MINK

    “It came up during the session,” Dr. Fischbeck told Neurology Today, “whether the severe adverse events in Dr. Yu’s trial could have been foreseen if more data about safety and efficacy had been shared by other investigators.”

    Because Ionis had developed the ASO for Huntington’s disease in which 88 cases of enlarged ventricles and three cases of frank hydrocephalus had been observed, he said, “Perhaps if they had been more forthcoming with their results in the Huntington’s trial and the large amount of animal testing that they had done over the years, there is a chance it might have prevented these unfortunate adverse events.”

    Ionis and the n-Lorem Foundation, Dr. Fischbeck said, “have a lot of data about not just this gene target but all the other gene targets they’ve studied,” Dr. Fischbeck said.

    The founder and former leader of Ionis, who now leads the n-Lorem Foundation, told Neurology Today that both organizations have been “100 percent forthcoming.”

    “We have offered to collaborate with everyone, including Tim,” said Stan Crooke, MD, PhD. “He, like every other investigator, has had multiple offers from us to collaborate. He chose for his own reasons to discover and develop this ASO himself and administer it without seeking our advice or participation.”

    Dr. Yu objected to that characterization. “We’ve been talking to Stan’s team for quite some time, ever since the original milasen,” Dr. Yu told Neurology Today. “For each of our programs, we’ve checked with a wide range of ASO and safety experts, including members of his Ionis team.”

    During the session on data sharing, Dr. Fischbeck said, Dr. Crooke said he was willing to share the data and expertise that n-Lorem has access to.

    “The question now is: will they be true to their word?” Dr. Fischbeck said. “What are the details going to be? But I think they’re’re opening the door to making the data available to investigators who want to put it to use.”

    Jonathan Mink, MD, PhD, FAAN, the Frederick A. Horner M.D. Distinguished Professor in Pediatric Neurology and Chief of Child Neurology at University of Rochester Medical Center, said he agreed that data sharing is essential for the development of ASOs.

    “We clinician-scientists are very quick to publish our successes and very slow to publish our failures,” Dr. Mink said. “There’s an awful lot of scientific research that never gets published but that could be very helpful. There is great potential with these ASOs, but we need to remember that these are experimental treatments. We’re learning that the human response is different from what was expected based on animal studies. It’s very important that we’re very cautious and that there is good reporting of results, both good and bad, as widely as possible.”

    Dr. Yu noted that the N=1 collaborative is designed to foster exactly that kind of data sharing.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleWhere Food Security Makes a Difference: Older Adults Who Use F… : Neurology Today
    Next Article Quitting, unionizing, working remotely — how workers fought back in 2022
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.